Tag: KDC-MN-1649

  • Fasudil

    Isoquinolinesulfonamide Rho-associated protein kinase (ROCK) inhibitor with vasodilatory, anti-inflammatory, and neuroprotective activity

    An isoquinolinesulfonamide kinase inhibitor developed by Asahi Kasei as the first clinically approved ROCK inhibitor, registered in Japan and China for cerebral vasospasm after subarachnoid hemorrhage, with expanding investigational applications in pulmonary hypertension, amyotrophic lateral sclerosis, and cardiovascular disease.

    Abstract

    Fasudil (HA-1077, AT-877), the isoquinolinesulfonamide derivative of the H-series protein kinase inhibitors first described by Hidaka et al. in 1984, is the only Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor approved for systemic clinical use and the first protein kinase inhibitor to receive regulatory approval for any indication. Developed by Asahi Kasei Pharma (Tokyo, Japan) and marketed as Eril, fasudil has been approved in Japan since 1995 and in China for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage, where it is standard of care in Japanese neurosurgical practice. The compound inhibits ROCK by competitive occupation of the ATP-binding domain, with a Ki of approximately 0.33 micromolar against ROCK activity and modest preferential selectivity for ROCK2 (Ki approximately 47 nanomolar) over ROCK1 (Ki approximately 76 nanomolar) in purified kinase assays. Off-target inhibition of protein kinase A, protein kinase G, protein kinase C, and myosin light chain kinase occurs at approximately 5- to 100-fold higher concentrations. The principal metabolic transformation is rapid hepatic conversion to hydroxyfasudil by aldehyde oxidase (not cytochrome P450), producing an active metabolite with ROCK inhibitory potency similar to or greater than the parent compound and a substantially longer plasma half-life (approximately 5.5 hours versus 0.55 hours for fasudil). This metabolic profile renders fasudil effectively a prodrug of hydroxyfasudil in the oral context. The clinical evidence base in cerebral vasospasm rests on a pivotal 267-patient double-blind placebo-controlled trial (Shibuya et al. 1992) demonstrating significant reductions in angiographic vasospasm (38 versus 61 percent), symptomatic vasospasm (35 versus 50 percent), and poor outcome on the Glasgow Outcome Scale (12 versus 26 percent), confirmed by a 1,462-patient postmarketing surveillance study and a meta-analysis of 8 trials (odds ratio 0.48 for symptomatic vasospasm). Head-to-head comparison with nimodipine demonstrated comparable or superior outcomes (74.5 versus 61.7 percent good clinical outcome). Expanding investigational programs span pulmonary arterial hypertension, where meta-analyses of up to 865 patients demonstrate significant reductions in pulmonary artery pressure, vascular resistance, and 6-minute walk distance with no serious adverse events; and amyotrophic lateral sclerosis, where the 120-patient ROCK-ALS Phase 2 trial confirmed safety, demonstrated significant electrophysiological biomarker preservation (motor unit number index), and confirmed cerebrospinal fluid penetration of the active metabolite at concentrations matching preclinical efficacy. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.